PO64 METRONOMIC CHEMOTHERAPY (CHT) COMBINATION OF VINORELBINE (VRL) AND CAPECITABINE (CAPE) IN HER2- ADVANCED BREAST CANCER (ABC) PATIENTS (PTS) DOES NOT IMPAIR GLOBAL QOL. FIRST RESULTS OF THE VICTOR-2 STUDY

age distribution at the time of MBC diagnosis: 41-57 years (n=3) and 76/79 years (n=2). Two patients had solitary metastatic lesions (bone, n=2; lung, n=1), one patient had extensive bone metastases, and one patient had multiple bony and pulmonary metastases. In only one of the five cases did the patient receive chemotherapy in the supposed palliative situation. Discussion: There are patients who, despite the diagnosis of distant metastases, may be considered cured of their disease; however, these cases are rare. The long-term survivors in our study cohort comprised a relatively heterogeneous group with regard to age at MBC diagnosis, therapy and metastatic sites. The factors contributing to the quite rare and felicitous case of long-term survival or even cure, can hardly be evaluated systematically and remain a black box. It appears, however, that aggressive chemotherapy-containing regimens, are not the key to solving the mystery of this black box.